The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Open accessAbstract
Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge in oncology. Here, we proposed molecular pathway-based algorithm for scoring of target drugs using high throughput mutation data to personalize their clinical efficacies. This algorithm was validated on 3,800 exome mutation profiles from The Cancer Genome Atlas (TCGA) project for 128 target drugs. The output values termed Mutational Drug Scores (MDS) showed positive correlation with the published drug efficiencies in clinical trials. We also used MDS approach to simulate all known protein coding genes as the putative drug targets. The model used was built on the basis of 18,273 mutation profiles from COSMIC database for eight cancer types. We found that the MDS algorithm-predicted hits frequently coincide with those already used as targets of the existing cancer drugs, but several novel candidates can be considered promising for further developments. Our results evidence that the MDS is applicable to ranking of anticancer drugs and can be applied for the identification of novel molecular targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“In melanoma, immune checkpoint inhibitors, and anti-BRAF target drugs like Vemurafenib and Dabrafenib dramatically increased the patient’s chances to respond to treatment and to increase survival (Chapman et al., 2011; Prieto et al., 2012).”
BackgroundThe Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
HMDB 4.0: the human metabolome database for 2018
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1089 · Cited by 3,438
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
GeneCards Version 3: the human gene integrator
Safran, M., Dalah, I., Alexander, J., Rosen, N., Iny Stein, T., Shmoish, M., Nativ, N., Bahir, I., Doniger, T., Krug, H., et al. (2010) · Database · doi:10.1093/database/baq020 · Cited by 2,088
DrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
The Reactome pathway knowledgebase
Croft, D., Mundo, A. F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M. R., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1102 · Cited by 1,889
PID: the Pathway Interaction Database
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., & Buetow, K. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn653 · Cited by 1,603
Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges
Khatri, P., Sirota, M., & Butte, A. J. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002375 · Cited by 1,566
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L., & Zeng, J. (2017) · Nature Communications · doi:10.1038/s41467-017-00680-8 · Cited by 916
DGIdb 3.0: a redesign and expansion of the drug–gene interaction database
Cotto, K. C., Wagner, A. H., Feng, Y.-Y., Kiwala, S., Coffman, A. C., Spies, G., Wollam, A., Spies, N. C., Griffith, O. L., & Griffith, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1143 · Cited by 885
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
Nishimura, D. (2001) · Biotech Software & Internet Report · doi:10.1089/152791601750294344 · Cited by 567
Rifaioglu, A. S., Atas, H., Martin, M. J., Cetin-Atalay, R., Atalay, V., & Doğan, T. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby061 · Cited by 529
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Computational prediction of human metabolic pathways from the complete human genome
Romero, P., Wagg, J., Green, M. L., Kaiser, D., Krummenacker, M., & Karp, P. D. (2004) · Genome Biology · doi:10.1186/gb-2004-6-1-r2 · Cited by 517
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
An overview of targeted cancer therapy
Padma, V. V. (2015) · BioMedicine · doi:10.7603/s40681-015-0019-4 · Cited by 459
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266 · cited 1×
“, 2010), mTOR inhibitors (Xie et al., 2016), hormone receptors (Ko and Balk, 2004), proteasomal components (Kisselev et al.”
BackgroundMani, K. M., Lefebvre, C., Wang, K., Lim, W. K., Basso, K., Dalla‐Favera, R., & Califano, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.2 · Cited by 205
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Li, H., Zeng, J., & Shen, K. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3377-3 · Cited by 201
Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00095-4 · Cited by 201
Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
TOREN, P., & ZOUBEIDI, A. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2601 · Cited by 163
Testicular Cancer: A Reflection on 50 Years of Discovery
Hanna, N., & Einhorn, L. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.0896 · Cited by 160
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R. A., Silver, D. P., Sledge, G. W., & Carey, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 159
Disialoganglioside GD2 as a therapeutic target for human diseases
Suzuki, M., & Cheung, N. V. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.986459 · Cited by 156
COSMIC: High‐Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Beare, D. M., Bindal, N., Bamford, S., Ward, S., Cole, C. G., Jia, M., Kok, C. Y., Boutselakis, H., De, T., et al. (2016) · Current Protocols in Human Genetics · doi:10.1002/cphg.21 · Cited by 149
Targeted cancer therapy – Are the days of systemic chemotherapy numbered?
Joo, W. D., Visintin, I., & Mor, G. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.09.008 · Cited by 143
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.008 · Cited by 143
Ozerov, I. V., Lezhnina, K. V., Izumchenko, E., Artemov, A. V., Medintsev, S., Vanhaelen, Q., Aliper, A. M., Vijg, J., Osipov, A. N., Labat, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms13427 · Cited by 143
Self-citationResistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
Vasey, P. A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601497 · Cited by 123
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
Azoury, S. C., Straughan, D. M., & Shukla, V. (2015) · Current Cancer Drug Targets · doi:10.2174/156800961506150805145120 · Cited by 116
Buzdin, A. A., Sorokin, M., Garazha, A., Sekacheva, M. I., Kim, E. L., Zhukov, N. V., Wang, Y., Li, X., Kar, S., Hartmann, C. J., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.003 · Cited by 112
Self-citationBuzdin, A. A., Zhavoronkov, A. A., Korzinkin, M., Venkova, L. S., Zenin, A., Smirnov, P. Y., & Borisov, N. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00055 · Cited by 95
Self-citationVascular endothelial growth factor‐targeted therapy in metastatic renal cell carcinoma
Rini, B. I. (2009) · Cancer · doi:10.1002/cncr.24227 · Cited by 85
Borisov, N., Terekhanova, N. V., Aliper, A. M., Venkova, L. S., Smirnov, P. Y., Roumiantsev, S. A., Korzinkin, M., Zhavoronkov, A. A., & Buzdin, A. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2548 · Cited by 81
Self-citationTourneau, C. L., Paolettí, X., Servant, N., Bièche, I., Gentien, D., Frio, T. R., Vincent‐Salomon, A., Servois, V., Roméjon, J., Mariani, O., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.211 · Cited by 78
Borisov, N. M., Suntsova, M., Sorokin, M., Garazha, A., Kovalchuk, O., Aliper, A. M., Ilnitskaya, E., Lezhnina, K. V., Korzinkin, M., Tkachev, V., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1361068 · Cited by 72
Self-citationOldenburg, J., Aparicio, J., Beyer, J., Cohn-Cedermark, G. E., Cullen, M. H., Gilligan, T. D., Giorgi, U. D., Santis, M. D., de Wit, R., Fosså, S. D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu514 · Cited by 70
Clinical development of mTor inhibitors for renal cancer
Ghidini, M., Petrelli, F., Ghidini, A., Tomasello, G., Hahne, J. C., Passalacqua, R., & Barni, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1384813 · Cited by 63
The anti-tumorigenic activity of A2M—A lesson from the naked mole-rat
Kurz, S., Thieme, R., Amberg, R., Groth, M., Jahnke, H., Pieroh, P., Horn, L., Kolb, M., Huse, K., Platzer, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189514 · Cited by 55
Self-citationExplaining the Unexplainable: EGFR Antibodies in Colorectal Cancer
Grothey, A. A., & Lenz, H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4194 · Cited by 53
Artemov, A. V., Aliper, A. M., Korzinkin, M., Lezhnina, K. V., Jellen, L. C., Zhukov, N. V., Roumiantsev, S. A., Гайфуллин, Н., Zhavoronkov, A. A., Borisov, N. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5119 · Cited by 53
Self-citationPoddubskaya, E. V., Baranova, M. P., Allina, D. O., Smirnov, P. Y., Albert, E. A., Kirilchev, A., Aleshin, A. A., Sekacheva, M. I., & Suntsova, M. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0113-x · Cited by 45
Mathematical Justification of Expression-Based Pathway Activation Scoring (PAS)
Aliper, A. M., Korzinkin, M., Kuzmina, N. B., Zenin, A., Venkova, L. S., Smirnov, P. Y., Zhavoronkov, A. A., Buzdin, A. A., & Borisov, N. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7027-8_3 · Cited by 40
Self-citationGiles, F. J., Cortes, J. E., & Kantarjian, H. M. (2005) · Current Molecular Medicine · doi:10.2174/156652405774641115 · Cited by 34
Towards identification of true cancer biomarkers
Diamandis, E. P. (2014) · BMC Medicine · doi:10.1186/s12916-014-0156-8 · Cited by 31
Buzdin, A. A., Prassolov, V., Zhavoronkov, A. A., & Borisov, N. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7027-8_4 · Cited by 29
Self-citationSpirin, P., Lebedev, T. D., Orlova, N., Morozov, A. V., Poymenova, N., Dmitriev, S. E., Buzdin, A. A., Stocking, C., Kovalchuk, O., & Prassolov, V. (2017) · Oncotarget · doi:10.18632/oncotarget.18503 · Cited by 28
Self-citationZaim, S. R., Li, Q., Schissler, A. G., & Lussier, Y. A. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0044 · Cited by 19
Gu, Y., Zhao, W., Xia, J., Zhang, Y., Wu, R., Wang, C., & Guo, Z. (2011) · Human Mutation · doi:10.1002/humu.21541 · Cited by 12
Research works printed but not linked: 8
- Buzdin, 2017, Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs, J. Clin. Oncol., 35, e23142, 10.1200/JCO.2017.35.15_suppl.e23142 · doi:10.1200/jco.2017.35.15_suppl.e23142
- 2017, Leading Causes of Death and Numbers of Deaths, by Sex, Race, and Hispanic Origin: United States, 1980 and 2016
- Hornberger, 2005, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am. J. Manag. Care, 11, 313
- Ko, 2004, Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers, Curr. Pharm. Biotechnol., 5, 459, 10.2174/1389201043376616 · doi:10.2174/1389201043376616
- Petrov, 2017, Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas, Oncotarget, 8, 83768, 10.18632/oncotarget.19662 · doi:10.18632/oncotarget.19662
- Sorokin, 2018, Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation, Oncotarget, 9, 5111, 10.18632/oncotarget.23700 · doi:10.18632/oncotarget.23700
- Wirsching, 2017, Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice, Surgery, 162, 68, 10.1016/j.surg.2017.01.032 · doi:10.1016/j.surg.2017.01.032
- Zhu, 2007, Application of a new probabilistic model for mining implicit associated cancer genes from OMIM and medline, Cancer Inform., 2, 361, 10.1177/117693510600200025 · doi:10.1177/117693510600200025
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?
Deleu, S., Machiels, K., Raes, J., Verbeke, K., & Vermeire, S. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103293 · Cited by 766
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment
Ornell, F., Moura, H. F., Scherer, J. N., Pechansky, F., Kessler, F. H. P., & von Diemen, L. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113096 · Cited by 308
Blockchain technology for a sustainable agri-food supply chain
Rana, R. L., Tricase, C., & De Cesare, L. (2021) · British Food Journal · doi:10.1108/bfj-09-2020-0832 · Cited by 261
Metadata
- Authors
- Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-23
- Volume
- 10
- Pages
- 1-1
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2912929199
- Cited by
- 531
- References
- 67
- FWCI
- 33.31
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Amazon Web Services
- Microsoft
- Russian Science Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.